Abstract Book - PDF - San Antonio Breast Cancer Symposium

CTRC-AACR San Antonio Breast Cancer Symposium
7:30 pm–10:00 pm
OPEN SATELLITE EVENT presented by Clinical Care Options
Marriott Rivercenter
Practical Answers to Your Clinical Challenges: Optimal Use of Bone-
Modifying Agents in Breast Cancer
WEBSITE: http://clinicaloptions.com/BoneHealthBreastCancer
Friday, December 7, 2012
6:45 am–5:15 pm
Registration
Bridge Hall
7:00 am–9:00 am
Poster Discussion 7: Neoadjuvant Endocrine Therapy &
Bisphosphonates
Ballroom A
Viewing 7:00 am
Discussion 7:45 am
Ruth O’Regan, MD, Chair and Discussant
Emory University School of Medicine
Atlanta, GA
and
Ingrid Mayer, MD, MSCI, Discussant
Vanderbilt University Medical Center
Nashville, TN
PD07-01 Z1031B neoadjuvant aromatase inhibitor trial: A Phase 2 study
of triage to chemotherapy based on 2 to 4 week Ki67 level
>10%
Ellis MJ, Suman V, McCall L, Luo R, Hoog J, Brink A, Watson M, Ma C,
Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther M, Dayao Z,
Leitch M, Ota D, Olson J, Hunt K, Allred C. Siteman Cancer Center,
Washington University, St Louis, MO; Mayo Clinic; Duke University;
Doctor’s Hospital of Laredo; Nashville Breast Center; MD Anderson
Cancer Center; St. Elizabeth Med Ctr Southwest; Univ of New Mexico;
UT Southwestern; University of Maryland Medical Center.
PD07-02 Anticancer activity of letrozole plus zoledronic acid as
neoadjuvant therapy for postmenopausal patients with breast
cancer: FEMZONE trial results
Fasching PA, Jud SM, Hauschild M, Kümmel S, Schütte M, Warm M,
Hanf V, Muth M, Baier M, Schulz-Wendtland R, Beckmann MW, Lux
MP. Erlangen University Hospital, Friedrich Alexander University of
Erlangen Nuremberg, Erlangen, Germany; Frauenklinik Rheinfelden,
Rheinfelden, Germany; Frauenklinik, Klinikum Essen-Mitte, Essen,
Germany; Essen University Hospital, Essen, Germany; Cologne
University Hospital, Cologne, Germany; Kliniken der Stadt Köln
Holweide, Cologne, Germany; Klinikum Fuerth, Fuerth, Germany;
Novartis Pharma GmbH, Nuremberg, Germany; Erlangen University
Hospital, Friedrich Alexander University of Erlangen–Nuremberg,
Erlangen, Germany.
PD07-03 Increased pathologic complete response rate after a long term
neoadjuvant letrozole treatment in postmenopausal estrogen
and/or progesterone receptor-positive breast cancer
Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S, Foroni C,
Milani M, Cappelletti MR, Generali D, Berruti A, Bottini A. A.O. Istituti
Ospitalieri di Cremona, Cremona, Italy; A.O.U. San Luigi Gonzaga di
Orbassano, Orbassano, TO, Italy.
PD07-04
PD07-05
PD07-06
PD07-07
PD07-08
A randomized phase II neoadjuvant trial evaluating
anastrozole and fulvestrant efficiency for post-menopausal
ER-positive, HER2-negative breast cancer patients: first results
of the UNICANCER CARMINA 02 French trial
Lerebours F, Bourgier C, Alran S, Mouret-Reynier M-A, Venat Bouvet
L, Kerbrat P, Salmon R, Mijonnet S, Becette V, Trassard M, Spyratos F,
Lebas N, Martin A-L, Lemonnier J, Mouret-Fourme E. Institut Curie,
Saint Cloud, France; Institut Gustave Roussy, Villejuif, France; Institut
Curie, Paris, France; Centre Jean Perrin, Clermont-Ferrand, France;
CHU, Limoges, France; Centre Eugene Marquis, Rennes, France; R&D
Unicancer, Paris, France.
A randomized controlled trial comparing zoledronic acid plus
chemotherapy with chemotherapy alone as a neoadjuvant
treatment in patients with HER2-negative primary breast
cancer
Hasegawa Y, Kohno N, Horiguchi J, Miura D, Ishikawa T, Hayashi
M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka
Y, Yamagami K, Akazawa K. Hirosaki Municipal Hospital, Hirosaki,
Aomori, Japan; Tokyo Medical University Hospital, Tokyo, Japan;
Gunma University Hospital, Maebashi, Gunma, Japan; Toranomon
Hospital, Tokyo, Japan; Yokohama City University Medical Center,
Yokohama, Kanagawa, Japan; Tokyo Medical University Hachioji
Medical Center, Hachioji, Tokyo, Japan; Hyogo Cancer Center, Akashi,
Hyogo, Japan; Osaka University Hospital, Suita, Osaka, Japan; Naga
Municipal Hospital, Kinokawa, Wakayama, Japan; Konan Hospital,
Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital,
Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, Osaka,
Japan; Shinko Hospital, Kobe, Hyogo, Japan; Niigata University
Medical and Dental Hospital, Niigata, Japan.
NEO-ZOTAC: Toxicity data of a phase III randomized trial with
NEOadjuvant chemotherapy (TAC) with or without ZOledronic
acid (ZA) for patients with HER2-negative large resectable or
locally advanced breast cancer (BC)
van de Ven S, Liefers G-j, Putter H, van Warmerdam LJ, Kessels LW,
Dercksen W, Pepels MJ, Maartense E, van Laarhoven HWM, Vriens B,
Smit VTHBM, Wasser MNJM, Meershoek-Klein Kranenbarg EM, van
Leeuwen-Stok E, van de Velde CJH, Nortier JWR, Kroep JR. Leiden
University Medical Center (LUMC), Leiden, Netherlands; Catharina
Hospital, Eindhoven, Netherlands; Deventer Hospital, Deventer,
Netherlands.
Prediction of antiproliferative response to lapatinib by HER3 in
an exploratory analysis of HER2-non-amplified (HER2-) breast
cancer in the MAPLE presurgical study (CRUK E/06/039)
Dowsett M, Leary A, Evans A, A’Hern R, Bliss J, Sahoo R, Detre S,
Hills M, Haynes B, Harper-Wynne C, Bundred N, Coombes G, Smith
IE, Johnston S. Royal Marsden Hospital, London, United Kingdom;
Institut Gustave Roussy, Paris, France; Poole Hospital, Poole, Dorset,
United Kingdom; Institute of Cancer Research, London, United
Kingdom; Kent Oncology Centre, Maidstone, Kent, United Kingdom;
University Hospital of South Manchester NHS Trust, Manchester,
United Kingdom.
Zoledronic acid specifically inhibits development of bone
metastases in the post-menopausal setting – evidence from
an in vivo breast cancer model
Holen I, Wang N, Reeves KJ, Fowles AM, Croucher PI, Eaton CL,
Ottewell PD. University of Sheffield, United Kingdom.
Cancer Res; 72(24 Suppl.) December 15, 2012 44s Cancer Research